VeraDermics, Inc.

VeraDermics, Inc. is a dermatologist-founded, late clinical-stage biopharmaceutical company based in New Haven, Connecticut, in the United States. The company was established with the specific mission of transforming the treatment of pattern hair loss (PHL), a condition it frames as a medical disease rather than a cosmetic inconvenience. According to its official materials, Veradermics was founded by dermatologists with direct clinical experience in treating pattern hair loss, and it positions itself around three core pillars: being designed with purpose, being evidence-led, and being patient-focused. The company's lead investigational product is VDPHL01, an extended-release oral tablet of minoxidil. Veradermics describes VDPHL01 as designed to be the first oral, non-hormonal FDA-approved therapy for pattern hair loss in both men and women. The product uses a proprietary extended-release technology intended to extend the exposure of minoxidil to hair follicles over time. The company notes that pattern hair loss is the largest aesthetics condition worldwide, yet no new prescription therapies have been introduced in nearly 30 years, and no oral prescription therapies have been approved by the U.S. Food and Drug Administration for women. Veradermics is conducting what it describes as one of the most comprehensive clinical development programs ever undertaken for pattern hair loss. This includes an open-label, multi-dose Phase 2 trial evaluating safety and efficacy in men and women with mild to moderate PHL, with primary endpoints of target area hair count and patient-reported outcomes. The company has also initiated three multicenter, randomized Phase 3 clinical trials of VDPHL01 in males and females, and has reported that enrollment in all three trials is complete. Positive preliminary results from the Phase 2 trial have been reported. The company is led by Chief Executive Officer Dr. Reid Waldman, a board-certified dermatologist with more than 10 years of clinical experience, who is also a board member. Under his leadership, Veradermics has raised significant equity financing and advanced VDPHL01 into Phase 3 trials. The company maintains an active investor relations presence, presenting at investor conferences and reporting quarterly financial results. Its headquarters is listed in New Haven, Connecticut, and its primary market focus is the United States.

VeraDermics, Inc. was founded by dermatologists who had direct clinical experience in the treatment of pattern hair loss. The company's formation was driven by the observation that pattern hair loss, despite affecting millions of people worldwide, had not seen meaningful therapeutic innovation in decades. According to the company, FDA-approved medications for pattern hair loss had not evolved in 30 years, and no oral prescription therapies had been approved by the FDA for women. Veradermics was established to bring clarity, evidence, and real scientific progress to hair loss care, treating pattern hair loss as a medical condition that deserves rigorous evidence, validated therapies, and clear guidance for patients. The company is headquartered in New Haven, Connecticut, United States. It describes itself as a late clinical-stage biopharmaceutical company. Its lead investigational product, VDPHL01, is an extended-release oral tablet of minoxidil created using proprietary extended-release technology designed to extend the exposure of minoxidil to hair follicles over time. VDPHL01 is being developed as a potential first oral, non-hormonal FDA-approved therapy for pattern hair loss in both men and women. Veradermics has undertaken a comprehensive clinical development program for VDPHL01. This includes an open-label, multi-dose Phase 2 trial evaluating safety and efficacy in men and women with mild to moderate pattern hair loss, with primary endpoints of target area hair count and patient-reported outcomes. Enrollment began first with males, and treatment continued in both male and female participants. The company reported positive preliminary results from the Phase 2 trial. Veradermics has also initiated three multicenter, randomized Phase 3 clinical trials of VDPHL01 in males and females with pattern hair loss. Enrollment in all three trials is complete, and the company has reported preliminary results. Under the leadership of CEO Dr. Reid Waldman, a board-certified dermatologist with more than 10 years of clinical experience, Veradermics has positioned itself for growth by implementing a differentiated strategy centered on advancing first-in-class therapeutics for under-innovated markets in aesthetics and dermatology. The company has successfully led significant equity financings and advanced VDPHL01 into Phase 3 trials. Veradermics maintains an active investor relations program, presenting at investor conferences and reporting quarterly financial results. Its mission is to set a new standard in pattern hair loss by developing therapies rooted in rigorous clinical evidence.

• Company founded by dermatologists to transform pattern hair loss treatment

• Phase 2 trial of VDPHL01 initiated; enrollment began with males

• Positive preliminary results reported from Phase 2 trial

• Three multicenter, randomized Phase 3 trials of VDPHL01 initiated

• Enrollment completed in all three Phase 3 trials

• July 17, 2026: Data from subgroup analysis of Phase 2/3 Study '302' in males presented at 2026 AAD Innovation Academy

• August 11, 2026: Second Quarter 2026 financial results reported

• September 3, 2026: Announced participation in upcoming September investor conferences

Late clinical-stage biopharmaceutical company developing the first potential oral, non-hormonal FDA-approved therapy for pattern hair loss in men and women, grounded in rigorous clinical evidence.

• VDPHL01

  Investigational extended-release oral tablet of minoxidil designed to be the first oral, non-hormonal FDA-approved therapy for pattern hair loss in men and women.

1. 1Dermatology Solutions | Veradermicsveradermics.com
2. 2About Us | Veradermicsveradermics.com
3. 3VDPHL01 | Non-Hormonal Oral Therapeutic for Hair Regrowthveradermics.com
4. 4About Pattern Hair Loss | Veradermicsveradermics.com
5. 5VeraDermics, Inc. (United States) - Wikidatawikidata.org